Amid controversy over withdrawn drug batches, an Indian pharmaceutical manufacturer calls for an international investigation, pledging transparency, independent testing and full cooperation with Sri Lankan health authorities.
The Indian pharmaceutical company Mann Pharmaceuticals has requested Sri Lankan health authorities to initiate an independent international investigation into the decision to withdraw several batches of ondansetron manufactured by the company, following concerns raised over the product.
In a formal letter addressed to the Director General of Health Services, the National Drug Regulatory Authority, the State Drug Corporation and the Medical Supplies Department, the company called for transparency and due process in reviewing the matter. Mann Pharmaceuticals stated that it is seeking clarity on the basis for the withdrawal decision and wishes to resolve the issue through accepted scientific standards.
The manufacturers informed Sri Lankan authorities that samples of the relevant drug batches will be sent to a recognized international laboratory for independent testing. The company has confirmed that it is prepared to bear the full cost of this testing to ensure impartial results.
In its communication, Mann Pharmaceuticals also requested that the samples released for testing be handled in strict compliance with required storage temperatures and regulatory standards. The company stressed that maintaining proper cold chain conditions is essential.
Mann Pharmaceuticals emphasized that it remains committed to addressing doubts regarding the quality, safety and efficacy of the drug in a prompt, transparent and responsible manner. The company stated that it values its reputation and engagement with Sri Lanka’s public health sector.
Copies of the letter have also been forwarded to the Minister of Health and the Secretary to the Ministry of Health, signaling the company’s intention to pursue an accountable resolution to the matter.
